• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Carolus Therapeutics

edit

Carolus Therapeutics, Inc. is a biopharmaceutical company committed to the development of innovative new drugs that will provide relief to patients suffering from a host of disorders triggered by acute and chronic inflammation. The clinical and commercialization focus of the company is on novel therapeutic strategies to noninvasively monitor and disrupt proinflammatory interactions of chemokines and prevent or reverse inflammation associated with a broad array of human diseases. The company’s patented technology represents a promising advance in inflammation therapy where the underlying disease, as opposed to the symptoms, is treated without significant side effect profiles.

Recent Milestones

edit

• 
  Carolus Therapeutics received $2.25M in Debt funding. (3/5/13)
  Posted 3/5/13 at 5:42pm via finsmes.com
• 
  Carolus Therapeutics added Court R. Turner as President, CEO and Director.
  Posted 3/5/13 at 5:42pm
• 
  Carolus Therapeutics added Douglas J. Downs as CFO.
  Posted 3/5/13 at 5:42pm

Videos

Screenshots

edit

Sources

1. Carolus Therapeutics Receives $2.25M Debt Facility from Square 1 Bank (finsmes.com) [edit]